 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...122123124125126127128129130131132...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed, Trial primary completion date, Metastases: SWOG-150506-80405-BRAF: Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=1142, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Jan 2100
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Jul 13, 2015
P2, N=0, Withdrawn, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Jan 2100 N=100 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 13, 2015
P2, N=21, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=100 --> 0 N=38 --> 21
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Pan tumor: An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status (clinicaltrials.gov) - Jul 13, 2015
P1, N=16, Completed, Sponsor: M.D. Anderson Cancer Center
N=38 --> 21 Active, not recruiting --> Completed | N=102 --> 16 | Trial primary completion date: May 2017 --> Jul 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Erlotinib in Combination With Cetuximab (clinicaltrials.gov) - Jul 13, 2015
P1, N=65, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=102 --> 16 | Trial primary completion date: May 2017 --> Jul 2015 Active, not recruiting --> Completed | N=48 --> 65 | Trial primary completion date: Apr 2016 --> Jul 2015
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jul 10, 2015
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | N=48 --> 65 | Trial primary completion date: Apr 2016 --> Jul 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment open: Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients (clinicaltrials.gov) - Jul 9, 2015
P2, N=24, Recruiting, Sponsor: Foamix Ltd.
Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: CHANCE: Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (clinicaltrials.gov) - Jul 9, 2015
P3, N=70, Completed, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: NoTOPain: Novel Treatment Option for Neuropathic Pain (clinicaltrials.gov) - Jul 6, 2015
P2, N=14, Not yet recruiting, Sponsor: Sorlandet Hospital HF
- ||| Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date: Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 6, 2015
P1/2, N=62, Not yet recruiting, Sponsor: Julie E. Bauman, MD, MPH
Active, not recruiting --> Completed Initiation date: Jan 2015 --> Sep 2015 | Trial primary completion date: Jan 2018 --> Sep 2018
- lumretuzumab (RG7116) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jul 6, 2015
P1, N=183, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2015 --> Sep 2015 | Trial primary completion date: Jan 2018 --> Sep 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
- duligotuzumab (MEHD7945A) / Roche
Enrollment closed, Trial primary completion date, Metastases: A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck (clinicaltrials.gov) - Jul 2, 2015
P2, N=122, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Aug 2014 --> Nov 2015 | Recruiting --> Active, not recruiting
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Jul 2, 2015
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2014 --> Nov 2015 | Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Apr 2017
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: ERMES: Erbitux MEtastatic Colorectal Cancer Strategy Study (clinicaltrials.gov) - Jun 30, 2015
P3, N=600, Recruiting, Sponsor: Carlo Barone
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: TAILOR: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (clinicaltrials.gov) - Jun 29, 2015
P3, N=503, Active, not recruiting, Sponsor: Merck KGaA
Trial primary completion date: Oct 2016 --> Apr 2017 Trial primary completion date: Jun 2015 --> Nov 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, Trial primary completion date, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jun 23, 2015
P1/2, N=30, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Jun 2015 --> Nov 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Jun 23, 2015
P2, N=80, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: ITACa: Sequential Treatment Strategy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 20, 2015
P3, N=350, Active, not recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 18, 2015
P2, N=65, Active, not recruiting, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, WNT974 / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Combination therapy, Metastases: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (clinicaltrials.gov) - Jun 17, 2015
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jan 2017 --> Jun 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 17, 2015
P1, N=21, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Jan 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- Trial primary completion date, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - Jun 15, 2015
P1, N=354, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study in Advanced Solid Tumors (clinicaltrials.gov) - Jun 12, 2015
P2, N=8, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Aug 2016 --> Sep 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) - Jun 11, 2015
P1, N=100, Recruiting, Sponsor: James Graham Brown Cancer Center
Trial primary completion date: Aug 2016 --> Sep 2015 Trial primary completion date: Jun 2015 --> Aug 2016
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial primary completion date, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov) - Jun 11, 2015
P1b, N=18, Recruiting, Sponsor: Daiichi Sankyo Inc.
Trial primary completion date: Jun 2015 --> Aug 2016 Trial primary completion date: May 2015 --> May 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, HEOR: Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Recruiting, Sponsor: National Center for Tumor Diseases, Heidelberg
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Dec 2013 --> Jul 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Biomarker, Trial primary completion date, FDG PET, Metastases: Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=25, Recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Dec 2013 --> Jul 2016 Trial primary completion date: Jan 2015 --> Jan 2016
- || merestinib (LY2801653) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY2801653 in Advanced Cancer (clinicaltrials.gov) - Jun 11, 2015
P1, N=190, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Mar 2016 --> Nov 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=59, Active, not recruiting, Sponsor: Martin Schuler, Prof. Dr. med.
Trial primary completion date: Mar 2016 --> Nov 2016 Trial primary completion date: Mar 2015 --> Dec 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Jun 11, 2015
P2, N=50, Recruiting, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Feb 2015 --> Feb 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Pan tumor: An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status (clinicaltrials.gov) - Jun 11, 2015
P1, N=102, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: May 2016 --> May 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=65, Recruiting, Sponsor: New Mexico Cancer Care Alliance
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Apr 2015 --> Dec 2015
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment change, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jun 11, 2015
P1, N=115, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2015 --> Dec 2015 N=70 --> 115
- gedatolisib (PF-05212384) / Celcuity
Enrollment change, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=19, Terminated, Sponsor: Pfizer
N=70 --> 115 N=150 --> 19
- | luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 6, 2015
P1, N=20, Completed, Sponsor: Swedish Medical Center
N=150 --> 19 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2015
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: MUTEX: Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable Fc?RIIa (CD32) Genotype (clinicaltrials.gov) - Jun 4, 2015
P2, N=72, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2015 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: DeLOS II: Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) (clinicaltrials.gov) - Jun 3, 2015
P2, N=180, Completed, Sponsor: ClinAssess
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Feb 2015
- |||| Biomarker, Enrollment open, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 1, 2015
P2, N=610, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Feb 2015 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> Mar 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Kisqali (ribociclib) / Novartis
Enrollment open, Metastases: CETLEE011: Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (clinicaltrials.gov) - May 29, 2015
P1, N=26, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> Mar 2019 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer (clinicaltrials.gov) - May 26, 2015
P=N/A, N=27, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> May 2015 | Trial primary completion date: Jun 2019 --> Jun 2020
- || telisotuzumab (h224G11) / AbbVie
Enrollment closed, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 22, 2015
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> May 2015 | Trial primary completion date: Jun 2019 --> Jun 2020 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Metastases: CTXMAB+RT: Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - May 19, 2015
P2, N=70, Terminated, Sponsor: Azienda USL 4 Prato
Recruiting --> Active, not recruiting N=140 --> 70 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> May 2015; insufficient recruitment
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, WNT974 / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Trial primary completion date, Combination therapy, Metastases: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (clinicaltrials.gov) - May 19, 2015
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
N=140 --> 70 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> May 2015; insufficient recruitment Not yet recruiting --> Recruiting | Trial primary completion date: May 2017 --> Jan 2017
- |||| sonolisib (PX 866) / Pfizer
Trial completion: Phase 1 and 2 Study of PX-866 and Cetuximab (clinicaltrials.gov) - May 19, 2015
P1/2, N=178, Completed, Sponsor: Oncothyreon Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: May 2017 --> Jan 2017 Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: EXTRA: A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer (clinicaltrials.gov) - May 19, 2015
P2, N=41, Completed, Sponsor: Peking University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: TACETUX: Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab (clinicaltrials.gov) - May 13, 2015
P=N/A, N=40, Completed, Sponsor: International Group of Endovascular Oncology
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2016 --> May 2015
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab (clinicaltrials.gov) - May 12, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Rambam Health Care Campus
Recruiting --> Completed | Trial primary completion date: May 2016 --> May 2015 Not yet recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer (clinicaltrials.gov) - May 12, 2015
P2, N=43, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
New P2/3 trial, Metastases: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - May 8, 2015
P2/3, N=605, Recruiting, Sponsor: Southwest Oncology Group